In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
BUSINESS
Shionogi Aiming at Clinical Trials of COVID-19 Treatment Candidates in FY2020
Shionogi is accelerating its drug discovery efforts for COVID-19 infection treatments, aiming to start clinical trials in FY2020, the company said on April 14. Shionogi has initiated collaborative research with the Hokkaido University Research Center for Zoonosis Control to identify…
To read the full story
Related Article
- Shionogi Chief Eyes Conditional Approval for COVID-19 Vaccine, Supply by Year’s End If OK’ed
May 11, 2021
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
- Shionogi Drops March-End Goal to Start Clinical Trials for COVID-19 Treatment
November 2, 2020
- Shionogi Preparing Commercial Production of COVID-19 Vaccine Simultaneously with Development
June 22, 2020
- Shionogi Aims to Begin Clinical Studies for COVID-19 Vaccine in 2020
April 28, 2020
BUSINESS
- FDA Approves Izervay’s Wider Label with No Dosing Duration Limit
February 14, 2025
- Susmed to Get 100 Million Yen Milestone after PMS App Trial Start
February 13, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Meiji Logs Operating Loss in Vaccine Biz on Kostaive Devaluation
February 12, 2025
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…